Jason A. Mouabbi: Another ADC promises to broaden the treatment horizon in HR+ metastatic breast cancer.

Jason A. Mouabbi, Assistant Professor at MD Anderson Cancer Center, made the following post on X/Twitter:

“Exciting news! Another ADC promises to broaden the treatment horizon in HR+ metastatic breast cancer.

Questions swirling in my mind:

1. HER2-low dilemma: Dato-DXd or T-DXd first? Can sequential use with the same drug conjugate (Deruxtecan) yield promising results?

2. How to choose between Sacituzumab & Dato-DXd? Can we sequence them?

So many queries, so few answers!

Hoping for a prospective registry to track ADC sequencing and unveil solutions to these questions and more!”

For more information click here.
Source: Jason A. Mouabbi/Twitter